Array BioPharma Inc. expanded its oncology collaboration with Genentech Inc. for the second time, securing a potential $50 million in additional research funding over the next three years. (BioWorld Today)

Lilly ICOS LLC plans to move tadalafil into a Phase III program for benign prostatic hyperplasia after it reached statistical significance in a Phase II proof-of-concept study. (BioWorld Today)

Once again beating consensus estimates, Genentech Inc. reported a strong third quarter driven by better-than-expected sales of Avastin and Herceptin, two products that are increasingly being prescribed off-label. (BioWorld Today)

As it prepares to bring two more of its internally discovered products into the clinic, Metabasis Therapeutics Inc. raised $41.3 million in a private placement of common stock and warrants. (BioWorld Today)

Cypress Bioscience Inc. lost more than half its value Thursday after announcing that a pivotal Phase III study of milnacipran missed its primary endpoint as a treatment for pain associated with fibromyalgia. (BioWorld Today)

News that the HIV drug Reverset needs another Phase II study, delaying pivotal trials, drove Incyte Corp.'s stock down by 41 percent Wednesday. The Wilmington, Del.-based company met with the FDA earlier this week to discuss Phase II data presented in July at an International AIDS Society conference in Rio de Janeiro, Brazil, as well as its plans to move into two Phase III trials. The agency, though, looking for confirmatory safety and efficacy data, requested another Phase II study. (BioWorld Today)